AMENDMENTS TO THE CLAIMS

1. **(Previously Presented)** A compound of the formula Z:



where;

A is CH or N;

R_1 is a substituent to a carbon atom in the ring containing A selected from

$-S(=O)_pRa$,

where Ra is $-C_1$-C_4 alkyl, -ORx, -NRxRx, -NHNRxRx, -NHNHC(=O)ORx, -NRxOH;

-C(=O)-Rb,

where Rb is $-C_1$-C_4-alkyl, ORx, -NRxRx, -NHNRxRx,

$-NHC_1$-C_3-alkyl-C(=O)ORx;

-NRxRc,

where Rc is H, C_1-C_4 alkyl, -NRxRx; -C(=O)Rd, -CN, $S(=O)_pRx$

where Rd is C_1-C_4-alkyl, -ORx, -NRxRx

$-C_1$-C_3-alkyl-O-C1-C3alkylC(=O)ORx;

$-C_1$-C_3-alkyl-COORx;

$-C_1$-C_3alkyl-ORx;

$-(O-C_1$-C_3alkyl$)_q$-O-Rx;

a 5 or 6 membered aromatic ring have 1-3 hetero atoms;

p and q are independently selected from 1 or 2;

Rx is independently selected from H, C_1-C_4 alkyl or acetyl; or a pair of Rx can together with the adjacent N atom form a pyrrolidine, piperidine, piperazine or morpholine ring;

R_2 is a substituent to a carbon atom in the ring containing A and is H, halo, cyano, C_1-C_4-alkyl, haloC_1-C_4-alkyl;

L is –O-, -S(=O)$_r$- or –CH_2-, where r is 0, 1 or 2;

R_3 is H, C_1-C_3 alkyl;

R_4-R_7 are independently selected from H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, haloC_1-C_6 alkyl, C_1-C_6 alkanoyl, haloC_1-C_6 alkanoyl, C_1-C_6 alkoxy, haloC_1-C_6 alkoxy, C_1-C_6 alkyloxyC_1-C_6 alkyl, haloC_1-C_6 alkyloxyC_1-C_6 alkyl, hydroxyC_1-C_6 alkyl, aminoC_1-C_6 alkyl, carboxyC_1-C_6 alkyl, cyanoC_1-C_6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

X is –$(CR_8R_8')_n$-D-$(CR_8R_8')_m$-;

T is O or S;

D is a bond, –NR_9-, –O-, -S-, -S(=O)- or –$S(=O)_2$-;

n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;

R_8 and R_8' are independently H, C_1-C_3 alkyl, haloC_1-C_3alkyl, hydroxy, or R_8 and R_8' together with their adjacent C atom is –C(=O)-

R_9 is independently H, C_1-C_3 alkyl;

and pharmaceutically acceptable salts and prodrugs thereof;

with the proviso that R_1 as –C(=O)Rb is not morpholinoketo-.

2. **(Original)** A compound according to claim 1, wherein T is O.

3. **(Original)** A compound according to claim 1, wherein R_3 is H.

4. **(Previously Presented)** A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial formulae:



where X is as defined, Y is the bond to the (substituted) phenyl ring depicted in formula I and Z is the bond to the (thio)urea-pyridyl moiety depicted in formula Z.

5. **(Original)** A compound according to claim 1 wherein the compound of formula Z comprises an enantiomeric excess of the isomer showing negative optical activity.

6. **(Original)** A compound according to claim 1, wherein D is –O-

7. **(Original)** A compound according to claim 6, wherein n is 0 and m is 1.

8. **(Original)** A compound according to claim 1, wherein R4 is hydrogen, fluoro or hydroxy.

9. **(Original)** A compound according to claim 1, wherein R5 is hydrogen, fluoro, C1-3 alkylcarbonyl or C1-3alkyloxy.

10. **(Original)** A compound according to claim 1, wherein R6 is hydrogen, halo, C1-C3alkyloxy, C1-3alkylcarbonyl, cyano or ethynyl.

11. **(Original)** A compound according to claim 10, wherein R6 is hydrogen, methoxy or fluoro.

12. **(Original)** A compound according to claim 1, wherein R7 is hydrogen, cyano, halo, C1-3alkyloxy, or C1-3alkylcarbonyl.

13. **(Original)** A compound according to claim 12, wherein R7 is cyano, fluoro or acetyl.

14. **(Original)** A compound according to claim 1, wherein R5 and R6 are H and R4 and R7 are fluoro.

15. **(Original)** A compound according to claim 1, wherein R4 is fluoro, R5 and R6 are H, and R7 is cyano or acetyl.

16. **(Original)** A compound according to claim 1, wherein L is –O-.

17. **(Original)** A compound according to claim 1, wherein R1 is -S(=O)2NRxRx, S(=O)2C1-C4 alkyl, or S(=O)C1-C4 alkyl.

18. **(Original)** A compound according to claim 17, wherein R1 is –S(=O)2NH2, –S(=O)2NMe2 or –S(=O)2NH-cyclopropyl.

19. **(Original)** A compound according to claim 17, wherein R1 is -S(=O)2Me or –S(=O)Me.

20. **(Original)** A compound according to claim 1, wherein R1 is –C(=O)ORx, -C(=O)NRxRx, -C(=O)NHNRxRx or -C(=O)NHCH2COORx.

21. **(Original)** A compound according to claim 20, wherein R1 is –C(=O)OH, -C(=O)OMe, -C(=O)NH2, -C(=O)NHMe, -C(=O)NHNH2, -C(=O)NHCH2COOH.

22. **(Original)** A compound according to claim 20, wherein R1 is –C(=O)NRx'-N-morpholine, –C(=O)NRx'-N-piperidine, –C(=O)NRx'-N-pyrrolidine or –C(=O)NRx'-N-piperazine, where Rx is methyl, acetyl or preferably H.

23. **(Original)** A compound according to claim 1, wherein R1 is –NRxRx, –N(C=O)C1-C4-alkyl or -NHC(=O)CH2OC1-C3-alkyl-COORx.

24. **(Original)** A compound according to claim 23, wherein R1 is –NH2, -NHC(=O)Me or NHC(=O)CH2OCH2C(=O)OH.

25. **(Original)** A compound according to claim 1, wherein R1 is -C1-C3-alkyl-COORx; -C1-C3alkyl-ORx, -(O-C1-C3alkyl)q-O-Rx or a 5 membered ring having 1-3 hetero atoms.

26. **(Original)** A compound according to claim 25, wherein R1 is carboxyethyl or a methyl ester thereof, 2-methoxyethoxyethoxy or triazolyl.

27. **(Original)** A compound according to claim 1, wherein R1 is para to the ether linkage.

28. **(Original)** A compound according to claim 1, wherein the ring containing A is phenyl or pyrid-3-yl.

29. **(Original)** A compound according to claim 1, wherein R2 is hydrogen or fluoro.

30. **(Original)** A compound according to claim 1 where R2 is meta to the ether linkage.

31. **(Currently amended)** A compound according to claim 1 denoted N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea



32. **(Original)** A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.

33. **(Original)** A composition according to claim 32, further comprising 1 to 3 additional HIV antivirals.

34. **(Original)** A composition according to claim 32, further comprising a cytochrome P450 modulator, such as ritonavir.

35. **(Previously Presented)** A method for the prophylaxis or treatment of HIV-1 infections comprising administering to an individual in need thereof an effective amount of the compound according to claim 1.

36. **(Previously Presented)** The method according to claim 35, wherein the HIV-1 infection is a drug escape mutant.

37. **(Previously Presented)** The method according to claim 36, wherein the drug escape mutant comprises the L100I and K103N mutations.

38. **(Currently Amended)** The method according to claim 35, wherein said compound is N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea



39. **(Previously presented)** The method according to claim 35, wherein the administration is vaginal.